Comparing the current results to its competitors, Y Mabs Therapeutics Inc reported Revenue decrease in the 2 quarter 2025 year on year by -17.26 %, despite the revenue increase by the most of its competitors of 9.4 %, recorded in the same quarter.
Y mabs Therapeutics inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 48.62 %
Y Mabs Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes large and specialty pharmaceutical and biotechnology firms, academic research institutions, governmental agencies, and both public and private research organizations. In the field of immunotherapy, competition arises from various biotechnology and large pharmaceutical companies, many of which possess greater financial resources and expertise. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Smaller or early-stage companies also present competition, particularly through collaborative efforts. Competitors vie for personnel recruitment, clinical trial site establishment, patient enrollment, and acquisition of complementary technologies. United Therapeutics Corporation is a noted competitor, having commercialized Unituxin® (dinutuximab), an antibody targeting GD2-positive tumors, in the United States, Canada, and Japan, which is relevant to the company's product DANYELZA.
May 26, 2025
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a biopharmaceutical company dedicated to pioneering advancements in cancer treatment through radioimmunotherapy and antibody-based products, recently presented a trial in progress poster at the Advances in Neuroblastoma Research Meeting (ANR) held from May 25-28, 2025, in Washington, D.C. This poster highlighted their GD2-SADA PRIT (Precision Radioimmunotherapy) trial, focusing on recurrent or refractory metastatic solid tumors that express the GD2 antigen, a critical target in neuroblastoma treatment. Key Highlights from the PresentationThe GD2-SADA PRIT trial aims to evaluate the effectiveness of GD2-SADA, a novel therapeutic approach leveraging the targeting capab...
June 7, 2024
Y-mAbs Therapeutics, a pioneering biopharmaceutical company dedicated to advancing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has recently unveiled groundbreaking preclinical data on GD2-SADA. This exciting revelation holds immense promise for the future of cancer treatment. The Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting will be the platform to unveil this groundbreaking data, scheduled to occur from June 8 to 11, 2024, in Toronto, Canada. This article aims to examine the preclinical GD2-SADA data presented by Y-mAbs and its implications for revolutionizing cancer therapy.Background:Cancer remains a formidable global health challe...
Hutchmed China Limited operates on a vertically integrated platform, focusing on the discovery, development, and commercialization of targeted therapeutics for oncology and immunological diseases. The company employs a comprehensive business model that encompasses research and development, manufacturing, marketing, and sales in order to deliver innovative drugs to patients. By leveraging its internal capabilities and strategic partnerships, Hutchmed China aims to transform the treatment landscape and improve the lives of patients in China and around the world.
Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.
Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.
Rhythm Pharmaceuticals Inc's business model focuses on developing and commercializing therapies for rare genetic disorders that result in unmet medical needs.
Sources:
Y mabs Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Y mabs Therapeutics inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
